Hydroxyurea regulates the development and survival of B16 Melanoma Cells by upregulating MiR-7013-3p

miRNAs are a family of short, noncoding RNAs that are involved in many processes in melanoma cells. MITF acts as a master regulator of melanocyte function, development and survival by modulating various genes. Hydroxyurea (HU) is used to treat melanoma, and miRNA expression is altered after HU treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yi-Jie, Gao, Yan, Wang, Chang-Jiang, Han, Dong-Xu, Zheng, Yi, Wang, Wen-Hua, Jiang, Hao, Yuan, Bao, Zhang, Jia-Bao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976580/
https://www.ncbi.nlm.nih.gov/pubmed/33746605
http://dx.doi.org/10.7150/ijms.52177
Descripción
Sumario:miRNAs are a family of short, noncoding RNAs that are involved in many processes in melanoma cells. MITF acts as a master regulator of melanocyte function, development and survival by modulating various genes. Hydroxyurea (HU) is used to treat melanoma, and miRNA expression is altered after HU treatment in B16 melanoma cells. In this study, we screened for miRNAs that were upregulated after HU treatment and that targeted the MITF gene. We found that miR-7013-3p exhibited increased expression after HU treatment and could bind to MITF. miR-7013-3p inhibited melanin production, proliferation, and migration and promoted apoptosis in B16 melanoma cells. The results may provide more information on the roles of miR-7013-3p in B16 melanoma cells.

Ejemplares similares